

[Esomeprazole]

GASTRO-ENTEROLOGY

GENERIC FORM OF NEXIUM®

STRENGTHS AND PHARMACEUTICAL FORMS:

20 - 40 mg, Delayed release pellets in capsules, Multicaps®

PHARMACOLOGICAL AND THERAPEUTIC PROPERTIES:

Esomeprazole is indicated in the treatment of gastro-oesophageal reflux disorder and risk reduction of non steroid anti inflammatory drug-associated gastric ulcers.

Esomeprazole is the S-isomer of omeprazole and reduces gastric acid secretion through a specific targeted mechanism in action. It is a specific inhibitor of the acid pump in the parietal cell. Esomeprazole is indicated in the treatment of erosive reflux oesophagitis, of gastro-oesophageal reflux disease. It is also indicated in the prevention and the treatment of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk.

CTD DOSSIERS:

Comparative bioavailability study with the reference product Nexium®, following a single dose administration, in fed and fasting conditions.
CTD dossier available in the US.

CONTACT: licensing@ethypharm.com